CA2345632A1 - Echange de gaz et de chaleur au moyen d'une ventilation mixte par liquide - Google Patents
Echange de gaz et de chaleur au moyen d'une ventilation mixte par liquide Download PDFInfo
- Publication number
- CA2345632A1 CA2345632A1 CA002345632A CA2345632A CA2345632A1 CA 2345632 A1 CA2345632 A1 CA 2345632A1 CA 002345632 A CA002345632 A CA 002345632A CA 2345632 A CA2345632 A CA 2345632A CA 2345632 A1 CA2345632 A1 CA 2345632A1
- Authority
- CA
- Canada
- Prior art keywords
- pfc
- gas
- liquid
- temperature
- ventilation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 239
- 238000009423 ventilation Methods 0.000 title abstract description 147
- 210000004072 lung Anatomy 0.000 claims abstract description 152
- 238000000034 method Methods 0.000 claims abstract description 106
- 238000002156 mixing Methods 0.000 claims abstract description 37
- 230000002631 hypothermal effect Effects 0.000 claims abstract description 22
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 358
- 239000007789 gas Substances 0.000 claims description 215
- 238000001802 infusion Methods 0.000 claims description 134
- 238000001816 cooling Methods 0.000 claims description 92
- 230000001965 increasing effect Effects 0.000 claims description 46
- 238000011068 loading method Methods 0.000 claims description 44
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000001307 helium Substances 0.000 claims description 8
- 229910052734 helium Inorganic materials 0.000 claims description 8
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 6
- 238000007906 compression Methods 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 208000005333 pulmonary edema Diseases 0.000 claims description 5
- 210000000621 bronchi Anatomy 0.000 claims description 4
- 239000002840 nitric oxide donor Substances 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 206010019345 Heat stroke Diseases 0.000 claims description 3
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims description 3
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 239000012620 biological material Substances 0.000 claims description 3
- 230000002977 hyperthermial effect Effects 0.000 claims description 3
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 206010020741 Hyperpyrexia Diseases 0.000 claims description 2
- 206010020844 Hyperthermia malignant Diseases 0.000 claims description 2
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000007004 malignant hyperthermia Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 5
- 206010013647 Drowning Diseases 0.000 claims 1
- 230000001706 oxygenating effect Effects 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 230000001360 synchronised effect Effects 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 abstract description 4
- 230000036031 hyperthermia Effects 0.000 abstract description 4
- 230000006698 induction Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 description 125
- 239000008280 blood Substances 0.000 description 89
- 210000004369 blood Anatomy 0.000 description 89
- 238000002474 experimental method Methods 0.000 description 72
- 229910002092 carbon dioxide Inorganic materials 0.000 description 70
- 238000012546 transfer Methods 0.000 description 50
- 230000036760 body temperature Effects 0.000 description 40
- 239000012530 fluid Substances 0.000 description 39
- 210000001519 tissue Anatomy 0.000 description 33
- 241000282472 Canis lupus familiaris Species 0.000 description 28
- 210000002216 heart Anatomy 0.000 description 27
- 230000007423 decrease Effects 0.000 description 26
- 238000010792 warming Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 230000003519 ventilatory effect Effects 0.000 description 19
- 238000011067 equilibration Methods 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
- 208000014674 injury Diseases 0.000 description 17
- 239000001301 oxygen Substances 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 238000009792 diffusion process Methods 0.000 description 16
- 230000002093 peripheral effect Effects 0.000 description 15
- 241000282465 Canis Species 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 230000001351 cycling effect Effects 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 230000000747 cardiac effect Effects 0.000 description 10
- 230000000241 respiratory effect Effects 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 9
- 230000006735 deficit Effects 0.000 description 9
- 230000003434 inspiratory effect Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 206010047139 Vasoconstriction Diseases 0.000 description 6
- 230000004872 arterial blood pressure Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000001105 femoral artery Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000005399 mechanical ventilation Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010061688 Barotrauma Diseases 0.000 description 5
- 208000010496 Heart Arrest Diseases 0.000 description 5
- 206010020591 Hypercapnia Diseases 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 230000025033 vasoconstriction Effects 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 230000002612 cardiopulmonary effect Effects 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 4
- 229960001217 perflubron Drugs 0.000 description 4
- FYJQJMIEZVMYSD-UHFFFAOYSA-N perfluoro-2-butyltetrahydrofuran Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)OC(F)(F)C(F)(F)C1(F)F FYJQJMIEZVMYSD-UHFFFAOYSA-N 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000012935 Averaging Methods 0.000 description 3
- 206010008531 Chills Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000003123 bronchiole Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003191 femoral vein Anatomy 0.000 description 3
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002370 liquid polymer infiltration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000037323 metabolic rate Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000036316 preload Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001631 vena cava inferior Anatomy 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- CJFUEPJVIFJOOU-UHFFFAOYSA-N 2-perfluorobutyltetrahydrofuran Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C1CCCO1 CJFUEPJVIFJOOU-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910001006 Constantan Inorganic materials 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000003826 Respiratory Acidosis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000036757 core body temperature Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- GWUAFYNDGVNXRS-UHFFFAOYSA-N helium;molecular oxygen Chemical compound [He].O=O GWUAFYNDGVNXRS-UHFFFAOYSA-N 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000003166 hypermetabolic effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000008258 liquid foam Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000803 paradoxical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 210000003454 tympanic membrane Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- GFGSZUNNBQXGMK-UHFFFAOYSA-N 2-chloro-4-nitrobenzamide Chemical compound NC(=O)C1=CC=C([N+]([O-])=O)C=C1Cl GFGSZUNNBQXGMK-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010044520 Traumatic delivery Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000009021 linear effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000009022 nonlinear effect Effects 0.000 description 1
- 230000037000 normothermia Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000008695 pulmonary vasoconstriction Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0054—Liquid ventilation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/105—Filters
- A61M16/106—Filters in a path
- A61M16/107—Filters in a path in the inspiratory path
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un nouveau procédé de ventilation et d'échange de chaleur appelé ventilation par liquide en mode mixte (MMLV : mixed mode liquid ventilation). Ce procédé comprend l'utilisation d'un cathéter endothrachéal (fig. 1a et 6b) permettant d'ajouter et de retirer du liquide des poumons de manière continue et/ou cyclique, et d'administrer un gaz à un débit indépendant de l'administration de liquide. Ce procédé produit un mélange de gaz et de liquide à petite échelle dans les voies respiratoires, permettant un échange efficace de gaz et de chaleur. L'invention concerne également des applications médicales de ce procédé, parmi lesquelles l'induction et l'inversion de l'hyperthermie et de l'hypothermie.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10259398P | 1998-10-01 | 1998-10-01 | |
| US60/102,593 | 1998-10-01 | ||
| PCT/US1999/022833 WO2000018459A1 (fr) | 1998-10-01 | 1999-10-01 | Echange de gaz et de chaleur au moyen d'une ventilation mixte par liquide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2345632A1 true CA2345632A1 (fr) | 2000-04-06 |
Family
ID=22290652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002345632A Abandoned CA2345632A1 (fr) | 1998-10-01 | 1999-10-01 | Echange de gaz et de chaleur au moyen d'une ventilation mixte par liquide |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1117455A4 (fr) |
| AU (1) | AU765816B2 (fr) |
| CA (1) | CA2345632A1 (fr) |
| WO (1) | WO2000018459A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002362045A1 (en) * | 2001-12-04 | 2003-06-17 | Minnesota High-Tech Resources, Llc | Breathable gas mixtures to change body temperature |
| WO2004082729A2 (fr) * | 2003-03-17 | 2004-09-30 | Aga Ab | Methode permettant de modifier la temperature corporelle d'un mammifere et dispositif a cet effet |
| CN100402103C (zh) * | 2003-05-22 | 2008-07-16 | 重庆海扶(Hifu)技术有限公司 | 排液通气呼吸系统 |
| JP4685799B2 (ja) | 2004-01-22 | 2011-05-18 | サーモキュア | 治療上の低体温を誘導するための呼吸器装置 |
| US10238831B2 (en) | 2013-09-08 | 2019-03-26 | Qool Therapeutics, Inc. | Temperature measurement and feedback for therapeutic hypothermia |
| WO2016138045A1 (fr) | 2015-02-23 | 2016-09-01 | Qool Therapeutics, Inc. | Systèmes et procédés pour l'administration endotrachéale de particules congelées |
| RU2748396C1 (ru) * | 2020-09-02 | 2021-05-25 | Михаил Васильевич Пригородов | Способ определения энергетической потребности пациента в критическом состоянии на спонтанном дыхании в режиме реального времени |
| CN112370271B (zh) * | 2020-10-30 | 2021-10-08 | 甘肃省人民医院 | 一种基于压力传感器对压力性损伤实时动态预防检测系统 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4232665A (en) * | 1979-01-10 | 1980-11-11 | Vaseen Vesper A | Portable lung apparatus |
| JP2935519B2 (ja) * | 1989-08-28 | 1999-08-16 | シーキンス，ケイ・マイケル | 超音波および／またはペルフルオロカーボン液での対流を介する肺癌高熱治療 |
| US5653685A (en) * | 1990-10-10 | 1997-08-05 | Lrt, Inc. | Method of providing circulation via lung expansion and deflation |
| US5437272A (en) * | 1991-05-01 | 1995-08-01 | Alliance Pharmaceutical Corp. | Perfluorocarbon associated gas exchange |
| AU667847B2 (en) * | 1991-11-14 | 1996-04-18 | Alliance Pharmaceutical Corporation | Method and apparatus for partial liquid ventilation using fluorocarbons |
| US5335650A (en) * | 1992-10-13 | 1994-08-09 | Temple University - Of The Commonwealth System Of Higher Education | Process control for liquid ventilation and related procedures |
| US5590651A (en) * | 1995-01-17 | 1997-01-07 | Temple University - Of The Commonwealth System Of Higher Education | Breathable liquid elimination analysis |
| US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
| AU713362B2 (en) * | 1996-03-08 | 1999-12-02 | Life Resuscitation Technologies, Inc. | Liquid ventilation method and apparatus |
| US5706830A (en) * | 1996-05-06 | 1998-01-13 | South Alabama Medical Science Foundation | Liquid ventilator system and use thereof |
-
1999
- 1999-10-01 CA CA002345632A patent/CA2345632A1/fr not_active Abandoned
- 1999-10-01 WO PCT/US1999/022833 patent/WO2000018459A1/fr not_active Application Discontinuation
- 1999-10-01 EP EP99956513A patent/EP1117455A4/fr not_active Withdrawn
- 1999-10-01 AU AU13110/00A patent/AU765816B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1117455A4 (fr) | 2003-01-29 |
| AU1311000A (en) | 2000-04-17 |
| EP1117455A1 (fr) | 2001-07-25 |
| WO2000018459A1 (fr) | 2000-04-06 |
| WO2000018459A9 (fr) | 2000-08-31 |
| AU765816B2 (en) | 2003-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6694977B1 (en) | Mixed-mode liquid ventilation gas and heat exchange | |
| JP2606994B2 (ja) | ペルフルオロカーボン介在ガス交換 | |
| Shin'oka et al. | Higher hematocrit improves cerebral outcome after deep hypothermic circulatory arrest | |
| Hill et al. | Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome) use of the Bramson membrane lung | |
| EP2192879B1 (fr) | Appareil portable et procédé pour l'administration d'un échange de chaleur dans les poumons de mammifère | |
| Jastrzebski et al. | Cardiorespiratory effects of protamine after cardiopulmonary bypass in man | |
| Shaffer et al. | Liquid ventilation in premature lambs: uptake, biodistribution and elimination of perfluorodecalin liquid | |
| US20020023640A1 (en) | Respiratory apparatus including liquid ventilator | |
| Legband et al. | Evaluation of peritoneal microbubble oxygenation therapy in a rabbit model of hypoxemia | |
| AU765816B2 (en) | Mixed-mode liquid ventilation gas and heat exchange | |
| Nielsen et al. | Apneic oxygenation combined with extracorporeal arteriovenous carbon dioxide removal provides sufficient gas exchange in experimental lung injury | |
| Harris et al. | Rapid (0.5 C/min) minimally invasive induction of hypothermia using cold perfluorochemical lung lavage in dogs | |
| Shaffer et al. | Liquid ventilation: an alternative ventilation strategy for management of neonatal respiratory distress | |
| US7909031B2 (en) | Process for transient and steady state delivery of biological agents to the lung via breathable liquids | |
| Carr et al. | Peritoneal perfusion with oxygenated perfluorocarbon augments systemic oxygenation | |
| Ichiba et al. | Modifying a venovenous extracorporeal membrane oxygenation circuit to reduce recirculation | |
| Brown et al. | Acute lung injury and acute respiratory distress syndrome: extracorporeal life support and liquid ventilation for severe acute respiratory distress syndrome in adults | |
| Wang et al. | Toward ambulatory arteriovenous CO2 removal: initial studies and prototype development | |
| Day et al. | Liquid ventilation | |
| Downing et al. | Acute physiological changes following heart-lung allotransplantation in dogs | |
| Lim et al. | Circulatory arrest during profound hypothermia induced by direct blood-stream cooling: An experimental study | |
| Lomholt | Continuous controlled humidification of inspired air | |
| Gross et al. | Supplemental systemic oxygen support using an intestinal intraluminal membrane oxygenator | |
| Alva et al. | A model of deep experimental hypothermia and rewarming in rat | |
| Bilge et al. | Peritoneal oxygenation a feasibility analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |